Textured Breast Implants and Lymphoma in Women Carrying BRCA1/2 Mutations

Balancing Appearance, Genetics, and Safety After Cancer Surgery

Breast reconstruction after cancer treatment is critical not only for appearance but also for psychological well-being. Yet the process has a less visible aspect: the long-term safety of implants.

Textured implants in particular may be associated with a rare but aggressive lymphoma, breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) . This association has become clearer in recent years. Moreover, a strong newly published study indicates that this risk increases substantially in women carrying BRCA1/2 mutations.

Drawing on a comprehensive study conducted jointly by Memorial Sloan Kettering Cancer Center (MSKCC) and the Netherlands Cancer Institute, published on June 12, 2025, in Blood Advances , this article examines BIA-ALCL's genetic background, its relationship with implant type, and current clinical recommendations.

🧬 BRCA1/2 Mutations and BIA-ALCL: A 16-Fold Increase in Risk!

Within a prospective cohort of 3546 women, the study examined 520 who underwent textured-implant reconstruction after breast cancer and had BRCA1/2 testing.

• The risk of BIA-ALCL in women carrying BRCA1/2 mutationswas 16 times higher than in noncarriers (HR: 15.2, 95% CI: 3.2–71.4, p=0.0006).
• A case-control analysis including 13 BIA-ALCL cases similarly found a significant association with BRCA mutations (p=0.0002).
• Other potential factors, including chemotherapy, radiotherapy, and bilateral implants, showed no significant association.

🧠 What Does It Mean?

BRCA1/2 genes are essential to DNA repair. Pathogenic mutations disrupt genomic stability, potentially predisposing not only to breast and ovarian cancer but also to rare immune-system malignancies. BIA-ALCL thus emerges in BRCA carriers as another cancer potentially arising from genomic instability .

🧪 Study Strengths

• Prospective follow-up: A long median follow-up of 8.1 years allowed reliable observation of disease development.
• High-quality genetic analysis: MSK-IMPACT analyzed BRCA and 90 cancer-predisposition genes. Outside BRCA, only 1 ATM mutation was detected.
• Ashkenazi founder mutations were also examined, but none were found in the BIA-ALCL cases.

🔄 Risk Differences Between Textured and Smooth Implants

1️⃣ Do Nontextured Implants Carry BIA-ALCL Risk?

No. Current scientific data show that smooth implants are not associated with BIA-ALCL development.

• According to the FDA's 2023 update, among 1264 reported BIA-ALCL cases, more than 95% were associated with macrotextured implants.
• Cases reported with smooth implants involve diagnostic uncertainty or are exceptional.

2️⃣ Are Textured Implants Still Manufactured?

Manufacture and use of macrotextured implants have stopped in most countries:

• US and EU: In 2019, the FDA recalled Allergan's BIOCELL products.
• Türkiye: TİTCK similarly ended macrotextured implant use.
• However, microtextured or nanotextured implants remain in use in some countries. Their risk levels are not yet fully defined.

👩‍⚕️ Clinical Applications and Recommendations

For BRCA Carriers:

• Women planning breast reconstruction should be offered BRCA testing.
• In BRCA-positive patients:
  • Smooth implants or
  • Autologous reconstruction using their own tissue should be considered as alternatives.
• BRCA-positive patients who already have textured implants require regular follow-up and individualized risk assessment .

🧭 Conclusion: Genetic Predisposition and a Silent Threat Beneath the Skin

This study provides the first strong evidence linking BIA-ALCL with genetic background as well as implant type. For BRCA1/2 carriers, breast reconstruction becomes more than an aesthetic choice: an oncogenetic decision .

Medical oncologists, plastic surgeons, and genetic counselorsshould assess this information together through a multidisciplinary, individualized approach.